Gut Check Time for GVHD Companies: BMT Tandem Meetings Review

The 2010 BMT Tandem Meetings were held in Orlando, Florida this past week [February 24-28, 2010].  Considered the premier event for hematopoietic cell transplantation [HCT] and cellular therapy, the annual event attracts more than 2,500 clinicians, transplant nurses, clinical research

Graft Versus Host Disease: Failures and Future Opportunities

In September 2009, Osiris Therapeutics, Inc. (OSIR) reported preliminary results from two Phase III trials evaluating its Prochymal product candidate for the treatment of acute Graft-versus-Host disease [GVHD].  Unfortunately, neither trial reached its primary endpoint, sending shares